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Summary
Lantibiotics are peptide antimicrobials containing the
thioether-bridged amino acids lanthionine (Lan) and
methyllanthionine (MeLan) and often the dehydrated
residues dehydroalanine (Dha) and dehydrobutyrine
(Dhb). While biologically advantageous, the incorpo-
ration of these residues into peptides is synthetically
daunting, and their production in vivo is limited to
peptides containing proteinogenic amino acids. The
lacticin 481 synthetase LctM offers versatile control
over the installation of dehydro amino acids and thi-
oether rings into peptides. In vitro processing of
semisynthetic substrates unrelated to the prelacticin
481 peptide demonstrated the broad substrate toler-
ance of LctM. Furthermore, a chemoenzymatic strat-
egy was employed to generate novel thioether
linkages by cyclization of peptidic substrates con-
taining the nonproteinogenic cysteine analogs homo-
cysteine and b-homocysteine. These findings are
promising with respect to the utility of LctM toward
preparation of conformationally constrained peptide
therapeutics.
Introduction
The prevalence of drug resistance in clinical settings as
a consequence of bacterial ingenuity in altering meta-
bolic pathways and/or cell morphology poses a persis-
tent threat to human health [1]. Surprisingly, bacterial
resistance to the lantibiotic nisin has been limited dur-
ing its prolonged and ubiquitous usage in the dairy in-
dustry [2]. Lantibiotics are a class of posttranslationally
modified antimicrobial peptides containing thioether
crosslinks called lanthionines [3]. The conformational
constraints induced by lanthionines are essential
for nisin’s antimicrobial activity through binding to the
cell wall biosynthetic intermediate lipid II [4, 5] and
forming pores in the bacterial cell membrane [6]. These
multiple modes of bactericidal action are believed to
account for the observed high efficacy of nisin (nM
MICs) as well as the slow emergence of resistance
[7]. Other lantibiotics with entirely different primary
and three-dimensional structures such as mersacidin
and cinnamycin also recognize with high affinity their
*Correspondence: vddonk@uiuc.edu
3 These authors contributed equally to this work.targets, lipid II [8] and phosphatidyl ethanolamine [9],
respectively, suggesting that the lanthionine motif is
a naturally privileged architecture for constraining pep-
tides into a bioactive conformation [3]. In fact, lanthio-
nines have very recently been found in morphogenetic
peptides involved in sporulation in the streptomycetes
[10, 11], demonstrating that their use extends beyond
antimicrobial peptides.
Synthetic lanthionine containing peptides have found
use as mimics of disulfides or as structures that limit the
conformational flexibility of bioactive compounds [12].
The lanthionine moiety also provides higher chemical,
proteolytic, and metabolic stability for such analogs
[13–15]. The biologically advantageous properties con-
ferred by cyclic lanthionine containing peptides may
therefore provide a framework for the design of a range
of therapeutic peptides containing these structures [16–
18]. Given the difficulty of installing lanthionine synthet-
ically [12], realization of this goal will be greatly aided by
a detailed understanding of the enzymes involved in
posttranslational modification.
Lantibiotics are ribosomally synthesized as precursor
peptides termed LanA (Lan is used as a generic label for
lantibiotic biosynthetic proteins). They consist of a leader
sequence and a propeptide region, which undergoes the
posttranslational modifications. The cyclic thioethers
are produced by a two-step process involving dehydra-
tion of Ser and Thr residues in the propeptide portion of
the LanA substrates to generate dehydroalanine (Dha)
and dehydrobutyrine (Dhb), respectively (Figure 1A).
The intramolecular thioether crosslinks are then intro-
duced by nucleophilic attack of cysteine residues within
the peptides onto the dehydro amino acids. In class I lan-
tibiotics like nisin, the dehydration is performed by
a LanB dehydratase, and the cyclization by a LanC en-
zyme. In contrast, for class II lantibiotics like lacticin
481, a single LanM protein (e.g., LctM) catalyzes both re-
actions (Figure 1B). Until recently, the lack of a functional
in vitro assay for the lantibiotic dehydratase and cyclase
enzymes restricted tests of their substrate selectivity to
in vivo mutagenesis experiments with the 20 proteino-
genic amino acids. Investigations of mutations in the
propeptide region of the lanA genes on lantibiotic pro-
duction have been conducted in engineered expression
systems for nisin, subtilin, mutacin II, cinnamycin, and
mersacidin [3, 18], and more recently lacticin 3147 [19].
Tests of substrate specificity have also involved the ex-
pression of fusions of the nisin leader peptide to short
nonlantibiotic peptides in Lactococcus lactis strains
bearing plasmid-encoded dehydratase and cyclase en-
zymes [17, 20, 21]. Collectively, these studies have
shown that lantibiotic biosynthetic enzymes have sub-
stantial tolerance with respect to the sequence of their
peptide substrates; however, several factors can limit
the information gained from in vivo experiments. In par-
ticular, when negative results are obtained regarding an
alteration of the structure of the substrate peptide, this
may be due to failure of the biosynthetic proteins, or al-
ternatively to poor expression of the mutant substrates,
inability of the wild-type transport proteins to secrete the
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(A) Formation of lanthionine (Lan) and methyllanthionine (MeLan) crosslinks from Ser and Thr residues by dehydration to dehydroalanine (Dha)
and dehydrobutyrine (Dhb), respectively, and subsequent stereoselective addition of Cys thiol groups to the Dha and Dhb residues.
(B) Biosynthesis of lacticin 481 [23, 44]. The dehydration of Ser/Thr residues and subsequent regio- and chemoselective cyclization of Cys
residues is catalyzed by a single enzyme, LctM. Subsequent proteolytic removal of the unmodified leader sequence from the modified pro-
peptide region by the bifunctional protease/transporter LctT leads to export of mature lacticin 481 to the extracellular milieu [45].processed mutants, breakdown of the analog products,
or potential toxicity of the nonnatural products to the
producing strain due to nonrecognition of the mutants
by the innate immunity proteins [22]. These limitations
associated with in vivo methods to determine substrate
specificity may be overcome by in vitro assays of pep-
tide substrates.
In this article, we discuss the in vitro substrate speci-
ficity of lacticin 481 synthetase (LctM) and document its
utility for peptide engineering. This enzyme performs
both the dehydration of a defined set of Ser and Thr
residues in the C-terminal region of the LctA substrate
peptide as well as the subsequent cyclization steps
(Figure 1B) [23–26]. Employing both site-directed muta-
genesis and expressed protein ligation techniques, we
demonstrate that LctM can dehydrate and cyclize
a wide spectrum of peptides containing both natural
and nonproteinogenic amino acids, allowing precise
control over the size of lanthionine rings. Furthermore,
a predictive model is presented for the sequence and
positional specificity of dehydration by LctM that allows
for rational design of modified peptides.Results and Discussion
Specificity of LctM Action and Biological Activity
of Lacticin Analogs
In our initial in vitro characterization of LctM activity, the
enzyme was shown to be tolerant of several single-point
mutants of its substrate LctA fused at the N terminus to
a hexa-His tag (His6-LctA) [23]. To extend the evaluation
of LctM substrate selectivity, an expanded set of site-
directed mutants of His6-LctA were tested as substrates
(Figure 2A). Mutations that lead to replacement of lan-
thionines with methyllanthionines and vice versa were
all tolerated (entries 2–4, Figure 2B) as was substitution
of Dhb at position 48 with a Dha (entry 5). One difference
in comparison with the physiological substrate involves
the accumulation of more substantial amounts of par-
tially processed substrates (M 2 x H2O, x = 1–3), al-
though the fully dehydrated product (M 2 4 H2O) gener-
ally remained the major product (e.g., Figure S1A; see
the Supplemental Data available with this article online).
After modification by LctM, the products were treated
with the protease Lys-C to remove the leader peptide
Substrate Promiscuity of Lacticin Synthetase
1111Figure 2. Mutants of Lacticin 481 and Their
Biological Activity
(A) The structure of wild-type lacticin 481
and the mutants tested in this study. The
ring designations are shown in bold capital
letters. Residue numbering refers to the
full-length wild-type LctA substrate that
includes the leader sequence but not the
His6-tag.
(B) Products of incubation of His6-tagged
LctA mutants with LctM. Biological activity
of lacticin 481 mutants (after proteolytic pro-
cessing with Lys-C) toward the indicator
strain L. lactis CNRZ 117 is indicated as +
(active) or 2 (inactive).as well as the Lys that normally occupies position 1 of
lacticin 481. This Lys is not essential for antimicrobial
activity [23]. The lacticin 481 analogs produced were
evaluated for their biological activity by a standard
agar diffusion assay versus a known susceptible indica-
tor strain, Lactococcus lactis CNRZ 117. The partially
processed substrates (e.g., Figure S1A) could not be re-
moved during HPLC purification preventing accurate
quantitation of the bactericidal activity of the analogs;
a qualitative assessment is presented in Figure 2B.
Mutation of one or more Cys residues or their respec-
tive Ser/Thr partners results in deletion of thioether rings
(entries 6–9). The removal of one or more of the rings
does not affect the dehydration of the Ser/Thr residues,
showing that the dehydratase activity of LctM is not cou-
pled to the cyclization activity. The antimicrobial assays,
on the other hand, clearly indicate the requirement for all
three Lan/MeLan rings in lacticin 481 for bactericidal ac-
tivity under these assay conditions. The requirement for
the A ring that is highly conserved in the lacticin 481 sub-
group of lantibiotics (Figure 3A) may reflect its similarity
with the C ring of mersacidin, which is critical for its
mode of action [27], binding to lipid II [8, 28]. The exact
nature of the thioether rings in lacticin 481, whether
Lan or MeLan, appears less important (entries 2–4), indi-
cating that it is the constraint imposed by the crosslink
that is critical. Indeed, several lantibiotics closely related
to lacticin 481 contain a methyllanthionine rather than
a lanthionine in the C ring (Figure 3A) [29, 30]. However,the electrophilic Dhb24 in the mature product (derived
from Thr48 in the LctA prepeptide) that is conserved in
these closest relatives is not absolutely necessary for bi-
ological activity of lacticin 481 as demonstrated by the
antimicrobial activity of the lacticin analogs produced
with the His6-LctA(T48S) and His6-LctA(T48A) mutants
(entries 5 and 10, Figure 2B). The deleterious effects of
removing Lan and/or MeLan rings on the biological ac-
tivity of lantibiotics has also been demonstrated for
Pep5 [14], mutacin II [30], and nisin [22].
Sequence and Position Dependence of Dehydration
by LctM
LctM acts upon the His6-LctA substrate in a site-specific
manner such that only four of the 14 possible reactive
serine and threonine residues undergo dehydration.
Nevertheless, introduction of an additional Ser residue
in the propeptide region of His6-LctA at position 49 re-
sulted in incorporation of a fifth dehydro amino acid
(entry 9, Figure 2B) suggesting that the selectivity for
four dehydrations is not strict. A recent comprehensive
analysis of all known lantibiotic structures identified
a weak consensus regarding the sequence context of
Ser/Thr residues that are dehydrated in the peptide sub-
strates [21]. In most cases, the dehydrated residues
were found to be flanked by at least one hydrophobic
residue with carboxylate side chains rarely present at
these positions. Especially uncommon is the combina-
tion of an Asp immediately N-terminal to Ser/Thr with
Chemistry & Biology
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(A) Primary sequence of the propeptide regions of several class II lantibiotics; for a more extensive list, see [29].
(B) Primary sequence of His6-wt-LctA and mutants thereof that were tested for dehydration by LctM. Mutations are highlighted in bold and
dehydrated residues are underlined. For nomenclature, see [46]. The sequence of the His6-tag leader peptide is GSSHHHHHHSSGL
VPRGSH-MKEQNSFNLLQEVTESELDLILGA.a C-terminally positioned arginine (D-S/T-R) [21]. These
results may in part reflect the generally high hydropho-
bicity and often net positive charge of lantibiotics, which
all target membranes or membrane-bound molecules
[3]. An analysis of the class II lantibiotic propeptides to
which lacticin 481 belongs [29] does not demonstrate
any clear recognition motifs (Figure 3A), although indeed
at least one flanking hydrophobic residue is typically
present and few Asp/Glu residues are found (4%). Given
the advantages of an in vitro system for evaluating a pos-
sible recognition motif, LctM was used toward this goal.
The effect of installing acidic residues adjacent to Ser/
Thr residues on the dehydration activity of LctM was
investigated with a series of site-directed mutants (Fig-
ure 3B, entries 2–4). Aspartates were introduced N-termi-
nal to Thr33, Ser35, and Ser42 as well as C-terminal to
Thr33, and the mutant substrates were incubated with
LctM. Interestingly, all proved to be good substrates for
LctM (Figure 2B, entries 11–13). Furthermore, conversion
of the ISH sequence at positions 34–36 to ISR and DSR
provided mutant substrates that were still dehydrated at
Ser35 (Figure2B,entries 13 and 14). These results demon-
strate that at least for lacticin 481 and its producing strain,
the paucity of acidic flanking residues reflects the desired
biological activity of the product and not the substrate
specificity of the synthetase LctM. These results are op-
posite those found for the dehydratase NisB involved in
nisin biosynthesis for which it was shown that serines
flanked by Asp and Arg were not substrates in nonlantibi-
otic test peptides [21]. The dehydratase domain of LctMhas no sequence homology with NisB, thus different sub-
strate specificity is not unexpected. Interestingly all ana-
logs showed antimicrobial activity after removal of the
leader peptide (Figure 2B, entries 11–14).
To explore the tolerance of LctM for sequences unre-
lated to its natural substrate, analogs were prepared by
using intein technology [31, 32], introducing synthetic
peptides behind the first 38 residues of LctA. The sub-
strate analogs were prepared from a MES (2-mercaptoe-
thanesulfonic acid) thioester of a truncated peptide,
His6-LctA(1–37), expressed in E. coli. This thioester
was ligated to several synthetic peptides (Figure 3B, en-
tries 6–8). Ligation with the heptamer CVISHEA yielded
His6-LctA(1–38)-VISHEA. In the appended sequence,
this peptide contains 6 simultaneous mutations of the
residues present in His6-LctA, and a new Ser is intro-
duced at position 41 where none is found in prelacticin
481 (Figure 3B). This peptide was chosen as it contains
the sequence ISH that undergoes dehydration in the
wild-type substrate. The peptide was subjected to
LctM and a triply dehydrated species was detected by
MALDI-TOF analysis of the assay products (Figure 4A).
Since two dehydrations occur at Ser33 and Thr35, the
presence of a peak in the mass spectrum corresponding
to three dehydrations indicates dehydration of Ser41.
Next, a substrate analog containing multiple ISH repeats,
His6-LctA(1–38)-VISHISHISHA, was synthesized by liga-
tion of the His6-LctA(1–37) thioester with the synthetic
dodecamer CVISHISHISHA and subjected to LctM under
standard assay conditions. The MALDI-TOF spectrum of
Substrate Promiscuity of Lacticin Synthetase
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MALDI-TOF mass spectra of (A) assay product of His6-LctA(1–38)-VISHEA with LctM (dashed) and a control assay without LctM (solid), (B)
assay product with His6-LctA(1–38)-VISHISHISHA (dashed) and control assay (solid), (C) assay product (dashed) and a control assay (solid)
for His6-LctA(1–38)-VGSGEA, and (D) assay product (dashed) and control (solid) for LctA(K25-G26insAAA)G27I/G29H. Phosphorylated pep-
tides are indicated by asterisks [25].the assay product clearly indicates formation of a spe-
cies corresponding to five dehydrations (Figure 4B).
These results, in conjunction with the dehydration of
Ser49 in the His6-LctA(C49S) mutant (Figure 2B, entry
9), suggest that LctM action is not position dependent,
a finding that has also been reported from recent in
vivo studies of the dehydratase NisB involved in nisin
biosynthesis [17, 33]. The ability to site-specifically intro-
duce Dha residues in this manner by both class I and
class II lantibiotic dehydratases holds promise for future
lantibiotic engineering [3, 22] as well as for introducing
electrophilic handles into proteins that can be site-selec-
tively modified via chemoselective reactions [34–36].
Based on these results, it is surprising that Ser28 es-
capes dehydration in the propeptide region of wt LctA.
Two possible explanations can be postulated. Either
Ser28 is too close to the leader peptide, or a Ser flanked
by two glycines is not a good substrate for LctM. A series
of experiments were carried out to distinguish between
these possibilities. First, the mutant His6-LctA(1–38)-
VGSGEA was generated by ligation of the His6-LctA(1–
37)-MES thioester with the synthetic heptapeptideCVGSGEA (Figure 3B, entry 8). Upon subjecting the
purified ligation product to LctM, just two dehydrations
were observed (Figure 4C). This finding, in conjunction
with the three dehydrations observed with His6-LctA(1–
38)-VISHEA (Figure 4A), suggests that two Gly residues
flanking a Ser indeed deactivate LctM for dehydration.
These results, however, do not rule out that the dis-
tance of Ser/Thr residues to the leader peptide is also
critical for dehydration by LctM. Hence, the genetic mu-
tant His6-LctA(G27I/G29H) was constructed in which the
ISH sequence motif that resulted in dehydration at three
positions unrelated to lacticin 481 was installed in place
of the GSG sequence of wild-type LctA (Figure 3B, entry
9). When submitted to LctM, Ser28 remained unmodified
in this peptide (Figure S1B). On the other hand, when the
sequence was moved more distal to the leader se-
quence by insertion of three alanines between Lys25
and Gly26 (Figure 3B, entry 10), five dehydrations were
observed, and Ser28 was dehydrated (Figure 4D). An
identical strategy was employed to move the GSG se-
quence more distant to the leader sequence (Figure 3B,
entry 11), and the insertion mutant underwent only four
Chemistry & Biology
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(A) Structures of methyllanthionine and analogs formed by the action of LctM on truncated substrates containing cysteine derivatives X as
discussed in the text. The changes compared to the parent structure (X = Cys) are highlighted in red. The stereochemistry at carbons 2
and 3 of the analogs is inferred from the known stereochemistry of enzymatic cyclization by LctM. The crystal structure of the NisC cyclase
[37] with which the cyclization domain of LctM has clear homology strongly suggests that this stereochemistry will be retained.
(B) Test for a free thiol as illustrated for LctA(1–38)S35A/C38Hcys via cyanylation of the LctM reaction product. Uncyclized assay product
would be cyanylated by CDAP (path I), whereas in the cyclized product no free thiols are available for cyanylation (path II).
(C) MALDI-TOF mass spectra of cyanylation assays of the reactions of LctA(1–38)S35A/C38b3-R-HCys (left) and LctA(1–38)S35A/C38D-Hcys
(right) with LctM. Control cyanylations of the substrates are shown as solids lines (M + 25) and assay products after treatment with CDAP
as dashed lines (M 2 H2O). Cyanylated products that would be formed if a free thiol were present in the assay product are indicated by a black
bar (M 2 H2O 2 H + CN).dehydrations when incubated with LctM (Figure S2).
Collectively, these results demonstrate that efficient de-
hydration by LctM requires the Ser to be at a certain dis-
tance C-terminal to the last amino acid of the leader se-
quence and that Gly residues flanking a Ser deactivate
its dehydration. These findings also provide further evi-
dence that the leader sequence is important for binding
and directing posttranslational modification of the pro-
peptide region [23, 37]. Understanding of the molecular
logic underlying these results requires structural infor-
mation and such studies are currently in progress.
Generation of Lanthionine Analogs
As discussed in the introduction, the lanthionine struc-
tural motif is a powerful and stable conformational con-
straint for bioactive peptides. Access to such structures
with the lantibiotic biosynthetic machinery is attractive
for both lantibiotic engineering and constraining other
bioactive peptides [16, 17], and precise control overthe size and stereochemistry of the rings at atomic res-
olution would be a powerful extension of current possi-
bilities. The ability of LctM to catalyze the formation of
(Me)Lan analogs was tested with truncated substrates
containing D-cysteine, L-homo, and D-homocysteine
(HCys), as well as the synthetic cysteine homologs b3-
(R)-homocysteine and b3-(S)-homocysteine [38] (Fig-
ure 5A). We chose for our tests a truncated substrate
in which Ser35 was replaced by Ala to minimize nonen-
zymatic processes since biomimetic studies show that
nonenzymatic cyclization of thiols onto dehydroalanines
can occur rapidly whereas the corresponding reactions
with dehydrobutyrines are slow [39–41]. Thus, the trun-
cated mutant LctA(1–37)S35A was purified as the MES
thioester and ligated to the Cys analogs (X) to generate
the corresponding mutants LctA(1–38)S35A/C38X (Fig-
ure 5A). These mutants were then subjected to LctM
under standard assay conditions and underwent the
expected single dehydration (Dhb33) by MALDI-TOF
Substrate Promiscuity of Lacticin Synthetase
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genic amino acids in the substrates did not affect the
dehydratase activity of LctM.
As both the uncyclized and cyclized assay products
have identical masses, they are indistinguishable by lin-
ear mode MALDI-TOF mass spectrometry. With this in
mind, a chemical approach for the detection of free thiols
was adopted (Figure 5B) [42]. Cyanylation of free thiols
with 1-cyano-4-dimethylaminopyridinium tetrafluorobo-
rate (CDAP) readily takes place under acidic conditions
(pH 3–5) [42] minimizing risk of nonenzymatic addition
of the thiol side chains of the cysteine analogs to
Dhb33. The enzymatic assay products were purified by
HPLC under acidic conditions and reacted with CDAP af-
ter reduction with tris(2-carboxyethyl)phosphine (TCEP)
to ensure that all uncyclized side-chain thiols were pres-
ent in the reduced reactive form. Representative results
from these experiments are presented in Figure 5C (for
all data see Figure S4). Cyanylation of a free thiol is ob-
served as a change in mass of +25 Da (M 2 H + CN) by
MALDI-TOF mass spectrometry. Control experiments
with the starting peptides indicated these were com-
pletely cyanylated (Figure 5C and Figure S4). In contrast,
cyanylation is not observed in the MALDI-TOF spectrum
of the enzymatic cyclization assay products indicating
that the enzyme is capable of generating the noncanon-
ical ring structures depicted in Figure 5A. The products
thus formed include stereoisomers of MeLan found in
natural lantibiotics as well as homologated products
that have one more atom in the ring or peptide backbone.
Although much effort was made to prevent complica-
tions of nonenzymatic cyclization, an unambiguous con-
trol experiment was sought in which a dehydrated sub-
strate could be incubated under the same reaction
conditions in the absence of enzyme. For this purpose,
a LctM mutant was needed that would retain dehydra-
tion activity but lacked any cyclization activity. The C ter-
minus of LctM has sequence homology with NisC, the
cyclase involved in nisin biosynthesis. NisC is a Zn pro-
tein [43], and its structure was recently solved revealing
the Zn ligands that are also conserved in LctM [37]. The
zinc is believed to activate the thiol of the substrate for
nucleophilic attack onto the dehydro amino acid. There-
fore, the conserved Zn ligand Cys836 in LctM was mu-
tated to Ala. As intended, LctM(C836A) retained dehy-
dration activity but lacked full cyclization activity
because a free thiol was detected in the dehydrated
LctA(1–38)S35A product (M.P., G.C.P., and W.A.v.d.D.,
unpublished data). With this cyclization-deficient LctM
mutant in hand, nonenzymatic cyclization could be ruled
out for the experiments discussed above, which un-
equivocally demonstrates that LctM has relaxed speci-
ficity with respect to the nucleophilic thiol.
Significance
We report a highly adaptable in vitro chemoenzymatic
route to access diverse structurally constrained mole-
cules that incorporate nonproteinogenic amino acids.
The bifunctional enzyme lacticin 481 synthetase is dem-
onstrated to have relaxed substrate specificity for both
its dehydratase and cyclase activities, allowing access
to lacticin 481 variants. Importantly, nonlantibiotic pep-
tides were also dehydrated by LctM, thereby installinga convenient electrophilic handle for further derivatiza-
tion. The only requirement appears to be the presence
of the leader peptide and a minimum distance between
the residue to be modified and this leader peptide.
This permits the utilization of semisynthetic substrates
that possess the lacticin 481 leader sequence and non-
lantibiotic C termini. The exact position of Ser/Thr resi-
dueswas less importantasdemonstratedbyboth the in-
sertion and extension mutants. While an analysis of
lantibiotic sequences and studies onNisB [21] suggest
that Asp and Glu residues flanking Ser/Thr may not be
conducive to dehydration, LctM is tolerant toward
these amino acids. On the other hand, Gly adjacent
to Ser is clearly demonstrated to impair the dehydra-
tion reaction. The cyclization reaction tolerates a vari-
ety of thiol substrates, which may be utilized to pre-
pare conformationally constrained bioactive peptides
with increased biostability. The use of nonproteino-
genic Cys analogs greatly expands the arsenal of ac-
cessible cyclic thioether structures by this mild and
convenient methodology.
Experimental Procedures
For detailed descriptions of the construction of genetic mutants, see
the online Supplemental Data.
General Protocol for LctM Activity Assays
RP-HPLC purified wt His6-LctA and mutant peptides were dissolved
in Millipore water and incubated with assay buffer containing 25 mM
Tris (pH 7.5), 5 mM MgCl2, 12.5 mg/ml BSA, and 2.5 mM ATP. Assays
were typically performed in the presence of 0.2 mM or 1 mM TCEP.
The mixtures were adjusted to pH 7.5 prior to addition of LctM and
then incubated at 25C for 2–4 hr. Control assays were under iden-
tical conditions without LctM. An assay aliquot was purified by
C18 Zip-tip and analyzed by MALDI-TOF mass spectrometry.
General Procedure for Bioassays
The RP-HPLC-purified wt His6-LctA and mutant peptides were dis-
solved in Millipore water to a final concentration >2 mg/ml. The pep-
tides (0.6–1.0 mg) were added to 50 mM Tris-HCl (pH 7.5), 10 mM
MgCl2, 25 mg/ml BSA, 5 mM ATP, and 5 mM ZnCl2. To drive the reac-
tions to completion as much as possible, His6-LctM (w40 mg) was
added every hour for 4 hr at 25C (total assay volume of 6 ml). Assay
mixtures were concentrated to 1 ml on a Labconco Centrivap Con-
centrator. The assay products were purified by C4 analytical RP-
HPLC with monitoring at 220 nm. Fractions containing product
were identified by MALDI-TOF MS, lyophilized, and resuspended
in 30 ml Millipore water. Commercially available protease Lys-C
(Roche) was resuspended in 50 ml 100 mM Tris (pH 8.3) to 0.4 mg/
ml final concentration. The purified assay product (w0.3 mg) was re-
suspended in 16 ml 100 mM Tris (pH 8.3) with 4 ml LysC and incubated
for 3 hr at 37C. Removal of the leader sequence from the mature
propeptide was confirmed by MALDI-TOF MS, and the mixture of
cleaved products evaporated to dryness. The products were redis-
solved in 5 ml sterile Millipore water. Freshly autoclaved GM17 agar
(4 % M17, 0.5 % glucose, and 1.5 % agar) was cooled to 50C, and
750 ml of an overnight culture of L. lactis CNRZ 117 (Centre National
de Recherches Zootechniques, Jouy-enJosas, France) in GM17
broth (4 % M17 and 0.5 % glucose) was added prior to pouring
plates. Wells were made in these agar plates with a sterile pipet
tip, and the cleavage products were applied. Autoclaved water
(5 ml) was applied as a negative control, while ampicillin (1 ml
100 mg/ml) or kanamycin (1 ml 50 mg/ml) served as a positive control.
Plates were incubated overnight at 25C and monitored for a zone of
clearance, which indicated lantibiotic activity.
General Peptide Synthesis
Peptides were synthesized on a 0.1 mmol or 0.05 mmol scale em-
ploying Fmoc-based solid-phase peptide synthesis protocols.
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ature in DMF. Deprotection of the Fmoc group was achieved with
20% piperidine in DMF for 4 3 5 min. Coupling of amino acids was
carried out for at least 1 hr with 0.4–0.8 mmol (four to eight equiva-
lents) of each Fmoc-AA and HBTU in the presence of 0.4 M N-meth-
ylmorpholine (NMM) in DMF. Couplings were monitored by the nin-
hydrin test. To minimize racemization Fmoc-L-Cys(Trt)-OH was
manually coupled in a base-free manner employing equimolar
amounts of DIC and HOBt. After completion of synthesis, the resin
was washed with DMF, ethanol, and DCM and dried in vacuo. Pep-
tide cleavage from the resin and global deprotection was achieved
with a mixture of TFA, water, and ethanedithiol (EDT, 95:2.5:2.5)
with the drop-wise addition of triisopropylsilane until a colorless
suspension was obtained. Crude peptides were precipitated and
washed with cold diethyl ether and lyophilized fromw10% aqueous
acetic acid after filtration through a 0.45 mm filter.
Lyophilized crude peptides were purified by C18 preparative
RP-HPLC, and the pure products were characterized by MALDI-
TOF MS. The calculated mass of the CVISHEA peptide was 758
Da, and the observed mass was 759 Da. The calculated mass of
the CVGSGEA peptide was 622 Da, and the observed mass was
623 Da. The calculated mass of the CVISHISHISHA peptide was
1303 Da, and the observed mass was 1304 Da.
General Expressed Protein Ligation Protocol
The RP-HPLC purified and lyophilized synthetic peptides were re-
dissolved in a minimum volume of ligation buffer (200–500 ml) con-
taining 100 mM HEPES (pH 7.75), 200 mM NaCl, 1 mM EDTA, and
50 mM MESNa to a final concentration of 32 mM (CVISHEA), 51
mM (CVGSGEA), or 14 mM (CVISHISHISHA). The peptide solution
was directly added to the lyophilized peptide thioester [25] to obtain
a final concentration of w1 mM of the thioester. The pH was ad-
justed to 7.6–7.8, and the reaction was kept at 4C for 12–16 hr.
The crude products were analyzed by MALDI-TOF MS for complete-
ness of the reaction prior to acidification with 5% TFA. The acidified
ligation mixture was incubated with 60 mM TCEP for 30 min at 25C
prior to purification by C4 analytical RP-HPLC.
Fractions containing the ligation products were analyzed by
MALDI-TOF MS. The calculated and the observed mass of His6-
LctA(1–38)-VISHEA was 6797 Da. The calculated and the observed
mass of His6-LctA(1–38)-VGSGEA was 6661 Da. The calculated
mass of His6-LctA(1–38)-V(ISH)3A was 7343 Da, and the observed
mass was 7344 Da.
Cyanylation Protocol
The LctM assay products were purified by C4 analytical RP-HPLC.
Fractions containing the assay products were evaporated to dry-
ness, and to each 1.7 ml Eppendorf tube containing assay product,
or an equivalent amount of the unmodified substrate, 5 ml denatur-
ation buffer (100 mM sodium citrate [pH 3.0], 6 M guanidine hydro-
chloride) and 10 ml reducing buffer (100 mM sodium citrate [pH
3.0], 100 mM TCEP) was added. The substrate and assay product
were redissolved by vortexing briefly and incubated at 25C for 15
min to reduce disulfide bonds. Then, 20 ml freshly prepared cyanyla-
tion solution (100 mM sodium citrate [pH 3.0], 100 mM CDAP) was
added to each tube. After an additional 15 min incubation at 25C,
the samples were acidified with 3 ml 5% aqueous TFA. The acidified
samples were purified by means of C18 Zip-tip and eluted with 3 ml
a-hydroxycinnamic acid matrix (prepared in 50% MeCN, containing
0.1% TFA) of which 1 ml was spotted directly on the MALDI target
and analyzed by MALDI-TOF.
Supplemental Data
Supplemental Data include procedures for the construction of LctA
mutant peptides as well as mass-spectrometry data for all peptides
and assays conducted and are available at http://www.chembiol.
com/cgi/content/full/13/10/1109/DC1/.
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